Startseite>>Signaling Pathways>> Neuroscience>>Levomedetomidine (hydrochloride)

Levomedetomidine (hydrochloride) (Synonyms: (R)-Medetomidine)

Katalog-Nr.GC49517

The levorotary enantiomer of medetomidine

Products are for research use only. Not for human use. We do not sell to patients.

Levomedetomidine (hydrochloride) Chemische Struktur

Cas No.: 190000-46-5

Größe Preis Lagerbestand Menge
1 mg
68,00 $
Auf Lager
5 mg
252,00 $
Auf Lager
10 mg
437,00 $
Auf Lager
25 mg
1.004,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Levomedetomidine is the levorotary enantiomer of the racemic α2-adrenergic receptor (α2-AR) agonist medetomidine.1 Unlike medetomidine or the dextrorotary enantiomer dexmedetomidine , levomedetomidine does not induce sedation or analgesia when administered alone in dogs.2 However, levomedetomidine does reduce the level of dexmedetomidine-induced sedation in dogs. Formulations containing levomedetomidine have been used as anesthetics.

1.Kim, S.M., Lee, B., An, H.J., et al.Novel PPARα agonist MHY553 alleviates hepatic steatosis by increasing fatty acid oxidation and decreasing inflammation during agingOncotarget8(28)46273-46285(2017) 2.Kuusela, E., Vainio, O., Kaistinen, A., et al.Sedative, analgesic, and cardiovascular effects of levomedetomidine alone and in combination with dexmedetomidine in dogsAm. J. Vet. Res.62(4)616-621(2001)

Bewertungen

Review for Levomedetomidine (hydrochloride)

Average Rating: 5 ★★★★★ (Based on Reviews and 22 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Levomedetomidine (hydrochloride)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.